The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Furiex Pharmaceuticals, Inc. (NasdaqGS:FURX) (“Furiex”) in connection with the sale of the Company to Forest Laboratories, Inc. (“Forest”).

Click here to learn about the case: http://docs.wongesq.com/FURX-Info-Request-Form-214. There is no cost or obligation to you.

Under the terms of the transaction, Furiex shareholders will receive $95.00 per share in cash for each share of Furiex stock they own. The transaction has a total approximate value of $1.1 billion. An additional $30.00 per share ($360 million in aggregate) may be payable to shareholders in a Contingent Value Right (CVR) based on the status of eluxodoline, Furiex’s lead product, as a controlled drug following approval. The investigation concerns whether the Furiex Board of directors breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Forest is underpaying for Furiex shares.

If you own common stock in Furiex and wish to obtain additional information, please contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/FURX-Info-Request-Form-214.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

Copyright Business Wire 2010